@article{96bd048708fb4b2eb21c4cf4d06d9086,
title = "Transforming the Activation of Clinical Trials",
abstract = "The Institute of Medicine and US Food and Drug Administration (FDA) recognize that activating clinical trials in the United States is lengthy and inefficient. Downstream consequences include increased expense, suboptimal accrual, move of clinical trials overseas, and delayed availability of treatments for patients. An in-tandem processing initiative is here highlighted that transformed the activation of clinical trials (TACT), reduced the activation time by 70%, and offers a paradigm for enhanced translational readiness.",
author = "Watters, {Julie T.} and Pitzen, {Jason H.} and Sanders, {Linda J.} and Bruce, {Virginia Nickie M.} and Cornell, {Alissa R.} and Cseko, {Gary C.} and Grace, {Janice S.} and Kwon, {Pamela S.} and Kukla, {Andrea K.} and Lee, {Michael S.} and Monosmith, {Michelle D.} and Myren, {John D.} and Kottschade, {Rebecca S.} and Shaft, {Marc N.} and Weis, {Jennifer Jenny A.} and Welter, {Jane C.} and Bharucha, {Adil E.}",
note = "Funding Information: This study was supported in part by Grant Number 1 UL1 RR024150-01* from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The funding source had no involvement with the study design; collecting, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics",
year = "2018",
month = jan,
doi = "10.1002/cpt.898",
language = "English (US)",
volume = "103",
pages = "43--46",
journal = "Clinical pharmacology and therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",
}